SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

Rocket Pharmaceuticals, Inc. backtest

10 trend-following strategies were compared on the full daily history of Rocket Pharmaceuticals, Inc.. 10 beat buy-and-hold CAGR; Supertrend ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is ADX / DI 방향성 (CAGR 5.6%, MDD -43.1%).

Data 2015-02-18 ~ 2026-07-31daily bars 2,880 (11.4 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -16.4%, drawdown -96.7%).

Sharpe leader (same as main): Supertrend — CAGR 10.5%, MDD -74.5%, Sharpe 0.38, 40% exposure.

Return/drawdown alternative: ADX / DI 방향성 — CAGR is 26.9%p higher than buy and hold, while drawdown improves by 22.2%p (CAGR 5.6%, MDD -43.1%, exposure 13%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
Supertrend
period=36, mult=4.9
10.5%-74.5%0.380.143.1x3140%
Parabolic SAR
step=0.02, maxStep=0.12
5.1%-86.2%0.330.061.8x22446%
ADX / DI 방향성
period=38, threshold=22
5.6%-43.1%0.330.131.9x1013%
SMA 크로스오버
fast=37, slow=43
-0.7%-92.3%0.31-0.010.9x10946%
MACD
fast=12, slow=57, signal=12
0.3%-94.9%0.310.001.0x14851%
Donchian 채널 돌파
entryN=21, exitN=69
-3.1%-92.4%0.31-0.030.7x3566%
ROC 모멘텀
n=41, threshold=0.08
1.3%-76.7%0.250.021.2x16635%
EMA 크로스오버
fast=67, slow=156
0.2%-75.2%0.210.001.0x1437%
Keltner 채널 돌파
emaPeriod=73, atrPeriod=28, mult=3.1
-0.9%-61.9%0.17-0.010.9x3021%
볼린저 밴드 돌파
n=32, k=3.5
0.8%-52.0%0.150.021.1x188%
Buy and hold-16.4%-96.7%0.26-0.170.1x1100%
0.1 1x 10x 2016 2018 2020 2022 2024 2026 SupertrendBuy and hold
Supertrend: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -24% -48% -73% -97% 2016 2018 2020 2022 2024 2026 Buy and holdSupertrend
Supertrend maximum drawdown -74.5% (2021-02-08 → 2026-07-31), prior peak not yet recovered.

Rules of the top strategy

Trades the direction of a volatility-based trend line that trails below/above price.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next